Floatz logo

Opakalim

Focal Epilepsy

Biohaven Therapeutics Ltd.Small moleculePhase 2/3Active
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
89/ 100

Competitive context

24 Active assets in the Focal Epilepsy cohort.

Asset / SponsorPhaseRating
Eslicarbazepine Acetate
Sumitomo Pharma America, Inc.
Phase 4A
Pregabalin
Yung Shin Pharm. Ind. Co., Ltd.
Phase 4A
Oxcarbamezapine
Mario Negri Institute for Pharmacological Research
Phase 4A
Topamax
Mario Negri Institute for Pharmacological Research
Phase 4A
Lacosamide
Jiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 4A

View all 50 →

Same molecule, other indications

Opakalim is also rated in:

bipolar disorderDormant
B
Indicative ·
60 / 100
View asset →
generalized epilepsyDormant
B
Indicative ·
57 / 100
View asset →
major depressive disorderDormant
CCC
Indicative ·
54 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →